ResultsIQ

ResultsIQ › Latest results › Amanta Healthcare Limited

Amanta Healthcare Limited Q3 FY26 earnings call summary

NSE: AMANTA · BSE: 544502

Earnings call of 11 Feb 2026, summarised by AI from the filing.

₹75 cr, up 9.8% YoY, driven by steady demand and volume-led expansion.

Key takeaways

  1. Q3 revenue ₹75 cr, up 9.8% YoY, driven by steady demand and volume-led expansion.
  2. SteriPort expansion Capacity doubling to roughly 12 cr bottles per year; commercialization in April 2026.
  3. Growth driver SteriPort incremental revenue ₹120 cr, plus or minus 4%-5%, from capacity expansion.
  4. Risk SVP ramp-up to sizeable EBITDA level will take one to two years due to regulatory approvals.

Original filing on BSE

Amanta Healthcare Limited Q1 FY27 results

As filed: Revenue ₹68.8 cr (+6% year on year), EBITDA ₹14.5 cr (−3% year on year), PAT ₹3.3 cr (−17% year on year), EBITDA margin 21.1% (−194 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹77.0 cr, EBITDA ₹15.0 cr, PAT ₹5.5 cr, EBITDA margin 19.4%. Not scored. No result for the same quarter last year. Share price after the results: +18.4% in 30 days (Nifty 500: +3.3%).
  • Q3 FY26: Revenue ₹74.5 cr, EBITDA ₹15.4 cr, PAT ₹4.6 cr, EBITDA margin 20.6%. Not scored. No result for the same quarter last year. Share price after the results: −7.2% in 30 days (Nifty 500: −7.5%).
  • Q2 FY26: Revenue ₹71.0 cr, EBITDA ₹15.0 cr, PAT ₹1.0 cr, EBITDA margin 21.1%. Not scored. No result for the same quarter last year. Share price after the results: −15.9% in 30 days (Nifty 500: −0.6%).
  • Q1 FY26: Revenue ₹65.0 cr, EBITDA ₹15.0 cr, PAT ₹4.0 cr, EBITDA margin 23.1%. Not scored. No result for the same quarter last year. Share price after the results: −9.5% in 28 days (Nifty 500: +4.3%).

Past price moves after results do not indicate future moves. Not a recommendation.

Amanta Healthcare Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.